1349 results for "Set and Setting"
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy.
Journal of psychopharmacology (Oxford, England) – April 01, 2025
Summary
A pivotal moment in modern psychiatry unfolds as psychedelics challenge traditional drug approval frameworks. The FDA's approach to MDMA therapy highlights a fundamental clash between conventional psychopharmacology, which views drugs as purely biological agents, and an emerging paradigm that recognizes the vital role of set and setting in treatment outcomes. This tension reflects a broader shift in how we understand mental health interventions, particularly when psychedelics are combined with therapy.
Abstract
The recent rejection of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy by the U.S. Food and Drug Administration (FDA) is a dramatic mome...
Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.
PsyArXiv – October 18, 2024
Summary
Beautiful psychedelic experiences lead to better mental health benefits. Research with 1,800 participants found that those who reported more aesthetically pleasing and meaningful psychedelic sessions experienced greater psychological insights and improved well-being. The findings suggest that setting and mindset significantly influence therapeutic outcomes during psychedelic experiences.
Abstract
Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.
JAMA Netw Open – July 01, 2024
Summary
Remarkably, the profound effects of a psychedelic journey aren't fixed. Scientists have found that altering a person's environment or music during the experience can profoundly shift its course. This reveals the crucial role context plays in shaping the mind's response. By intentionally manipulating these settings, we can better understand how these experiences work and enhance their positive therapeutic potential, offering new avenues for mental well-being.
Abstract
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
J Psychopharmacol – August 01, 2022
Summary
Many people reported significant reductions in depressive symptoms after a psychedelic experience. Researchers investigated how these experiences might impact mental well-being in a real-world setting. They tracked a large group over several weeks, observing changes in mood. The findings showed a notable and sustained improvement in depressive symptoms, suggesting the potential for these experiences to offer lasting mental health benefits.
Abstract
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
Clinical applications of hallucinogens: A review.
Exp Clin Psychopharmacol – August 01, 2016
Summary
Psychedelics are showing remarkable promise in medical settings. This review synthesizes growing evidence for their therapeutic potential, highlighting how substances like psilocybin and MDMA are being explored to treat complex mental health conditions. Findings reveal significant positive outcomes for patients struggling with depression, PTSD, and anxiety, often where traditional treatments have failed. The conclusion points to a future where carefully managed hallucinogen-assisted therapy could offer revolutionary new options for mental well-being.
Abstract
Clinical applications of hallucinogens: A review.
Potential Therapeutic Effects of Psilocybin.
Neurotherapeutics – July 01, 2017
Summary
Psilocybin is emerging as a powerful tool in mental health. Research explored its capacity to alleviate symptoms across various psychological conditions. Administered in controlled settings, it demonstrated remarkable efficacy, leading to significant improvements in patient well-being. The findings suggest a promising new avenue for addressing challenging mental health concerns, highlighting its potential as an impactful therapeutic agent.
Abstract
Potential Therapeutic Effects of Psilocybin.
Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
medRxiv – August 28, 2024
Summary
Many individuals report that psychedelic experiences can profoundly enhance their meditation. A recent investigation explored how personal traits, the psychedelic experience itself, and meditation habits interact to influence this connection. Researchers surveyed meditators with psychedelic experience, finding that specific factors like the intention set before a psychedelic journey and the subsequent integration practices significantly predicted improved meditation benefits, including deeper insights and sustained well-being. The findings suggest that when approached mindfully, psychedelics can positively contribute to deepening one's meditation practice.
Abstract
Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
J Psychopharmacol – April 22, 2021
Summary
The rapid development of psychedelic medicine can be greatly enhanced by modern research. This analysis proposes that integrating real-world data, pragmatic research, and digital technologies offers a powerful approach. By studying patient experiences in everyday settings and utilizing tools like apps, valuable insights are efficiently gathered. This provides a clearer picture of therapeutic benefits across diverse populations, demonstrating a robust pathway for advancing and integrating these innovative treatments into healthcare.
Abstract
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
Psychedelic Psychiatry's Brave New World.
Cell – April 01, 2020
Summary
Remarkably, certain psychedelic compounds are showing profound promise in treating severe mental health conditions. Researchers are exploring the hypothesis that these substances, when administered in controlled therapeutic settings, can facilitate significant psychological breakthroughs. Early clinical investigations, often involving guided sessions, have revealed impressive positive outcomes, including sustained reductions in symptoms of depression, PTSD, and anxiety. This suggests a powerful new paradigm for mental healthcare, offering hope for transformative healing.
Abstract
Psychedelic Psychiatry's Brave New World.
Harm reduction practises for users of psychedelic drugs: a scoping review.
Harm Reduct J – October 03, 2025
Summary
Many people are exploring psychedelic substances, making it vital to understand how to use them more safely. A comprehensive review aimed to identify and categorize current harm reduction approaches for those using them. Researchers systematically mapped existing literature, uncovering a range of practical strategies. These often involve education on dosage, setting, and potential interactions, alongside fostering supportive environments and promoting responsible decision-making. The findings highlight the effectiveness of these diverse harm reduction efforts in promoting safer experiences and better health outcomes for psychedelic users.
Abstract
Harm reduction practises for users of psychedelic drugs: a scoping review.
Levels of Vision
OpenAlex – October 16, 2024
Summary
Psilocybin directly alters how the human brain processes visual information, specifically affecting the suppression of visual input. This offers causal evidence for neurotransmitter receptors' role in vision. Utilizing Computer Science and Artificial Intelligence, a new Computer Vision model, based on a fundamental neural computation, was developed, outperforming previous approaches. Its algorithmic settings were linked to serotonin and GABA receptor density maps across the brain. Administering psilocybin systematically changed the model's suppression settings, providing new insights into ocular function and brain mechanisms.
Abstract
A goal of cognitive neuroscience is to provide accounts of brain functions in terms of information processing. Vision has long been used as a beach...
Music as a collaborating actor: new insights into the nature and role of music in psychedelic-assisted psychotherapy.
Frontiers in psychiatry – January 01, 2025
Summary
During psychedelic-assisted psychotherapy, music transforms from simple audio into a multisensory, personalized experience. Research shows that patients receiving psilocybin treatment in palliative care settings experienced music as an active collaborator in their healing journey, unlike those given placebo. The music became a therapeutic tool, creating deeply meaningful experiences that enhanced end-of-life care.
Abstract
Music has been identified as a central feature of psychedelic-assisted psychotherapy (PAP) and has hitherto been understood to amplify the psychede...
Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.
Drugs – May 01, 2025
Summary
Emerging evidence suggests psychedelic compounds like psilocybin and ayahuasca may offer new hope for people with treatment-resistant depression. When combined with therapy, these substances appear to help reset negative thought patterns and promote emotional breakthroughs. While showing promise in clinical trials, careful protocols and supervised settings remain essential for safety and effectiveness.
Abstract
There has been a recent resurgence in research on psychedelics as therapeutic agents for psychiatric conditions. This leading article outlines the ...
Psychedelics and autobiographical memory - six open questions.
Psychopharmacology – March 17, 2025
Summary
Psychedelics like LSD and psilocybin may hold unique potential for enhancing autobiographical memory and emotional processing. Research suggests these substances could help people access and reprocess important life memories in therapeutic settings. Key questions explore whether psychedelics improve memory recall, affect memory accuracy, and influence how meaningful experiences are remembered and integrated. This intersection of memory and consciousness could revolutionize mental health treatment.
Abstract
Since the earliest LSD research, psychedelics have been claimed to enhance autobiographical memory. Revisiting and processing autobiographical memo...
Licit use of illicit drugs for treating depression: the pill and the process.
The Journal of clinical investigation – June 17, 2024
Summary
Breakthrough treatments for depression may depend not just on the medication itself, but also on the therapeutic setting and support provided. Research shows that psychedelic medicines like psilocybin, MDMA, and ketamine work best when combined with professional psychological guidance. The patient's mindset and treatment environment significantly influence outcomes, suggesting these medications are most effective as part of a comprehensive therapeutic approach.
Abstract
Psilocybin, MDMA, and ketamine have emerged as potentially effective treatments for rapid amelioration of the symptoms of mood and related psychiat...
Assessing pharmaceutical and illicit drugs abuse in a university environment through wastewater analysis.
The Science of the total environment – March 15, 2025
Summary
Wastewater analysis reveals surprising drug consumption patterns in university settings. Scientists tracked 40 substances in campus wastewater using advanced surveillance techniques. The data showed high levels of antidepressants like venlafaxine, while cocaine was the most detected illicit drug. This innovative monitoring approach provides valuable insights into pharmaceutical and recreational drug use across the university environment.
Abstract
Monitoring the presence of illicit and pharmaceutical drugs in wastewater has emerged as a powerful tool for determining drug consumption patterns ...
A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.
Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association – April 01, 2025
Summary
Promising results show psychedelic-assisted therapy could help those facing serious illness find peace and meaning. When combined with expert support, carefully administered psilocybin helped reduce anxiety and depression in cancer patients while improving their spiritual wellbeing. Studies across multiple clinical settings confirm these treatments are safe and effective when properly screened and monitored.
Abstract
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence sugg...
Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.
Expert review of neurotherapeutics – February 01, 2025
Summary
Classic psychedelics like psilocybin, LSD, and DMT show remarkable promise in treating mental health conditions when used in controlled clinical settings. These 5-HT2a agonists, including mescaline and psilocin, demonstrate therapeutic potential with minimal risk of adverse effects or dependency. Research indicates these compounds could revolutionize psychiatric medicine by offering new treatment pathways for depression, anxiety, and addiction.
Abstract
After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during th...
Tags
Practical considerations in the establishment of psychedelic research programs.
Psychopharmacology – January 01, 2025
Summary
As psychedelics like LSD and psilocybin re-emerge in clinical research, medical centers face unique challenges in establishing legitimate studies. Setting up clinical trials requires careful navigation of regulatory hurdles, specialized facilities, and community engagement. Success hinges on early institutional support, proper drug handling protocols, and thorough DEA compliance. Despite obstacles, centers can build effective psychedelic research programs through methodical planning.
Abstract
There is increasing interest in establishing psychedelic research programs at academic medical centers. However, psychedelics are intensely psychoa...
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Molecular psychiatry – March 01, 2025
Summary
Despite decades of concern, psychedelic-induced psychosis is extremely rare, occurring in only 0.002% of general population cases. Analysis of multiple studies reveals that while risks increase slightly in clinical settings (0.2-0.6%), psychedelics appear safer than previously thought. However, people with schizophrenia show higher sensitivity, with about 4% experiencing lasting psychotic symptoms after use. These findings suggest current blanket restrictions may need careful reconsideration.
Abstract
Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. Howe...
Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment.
ACS medicinal chemistry letters – November 14, 2024
Summary
Naturally-occurring compounds 5-MeO-DMT and DMT show remarkable promise in treating severe mental health conditions. In controlled therapeutic settings, these substances produced rapid and significant improvements in depression and anxiety symptoms, with effects lasting weeks to months. New delivery methods and preparation techniques make treatments safer and more effective, while targeted approaches help specific groups like postpartum patients. Early results suggest these therapies could transform mental healthcare for those who haven't responded to traditional treatments.
Abstract
Recent advancements in the therapeutic use of psychedelic compounds, particularly 5-MeO-DMT and DMT, have demonstrated significant potential in tre...
Legal and Ethics Concerns of Psilocybin as Medicine.
The journal of the American Academy of Psychiatry and the Law – December 12, 2024
Summary
As psilocybin emerges as a groundbreaking treatment option, healthcare providers face complex challenges balancing patient care with legal requirements. While showing promise for mental health conditions, current regulations limit access to supervised clinical settings. Key concerns include ensuring proper informed consent, maintaining ethical standards of care, and addressing equity in treatment access. Legal frameworks continue evolving as medical evidence supports psilocybin's therapeutic potential.
Abstract
Preliminary research shows the psychedelic psilocybin to be a promising potential treatment for psychiatric illnesses. Recent U.S. government legis...
Ayahuasca drinking using a two-bottle choice procedure in male mice.
Scientific reports – October 23, 2024
Summary
Male mice given a choice between water and Ayahuasca showed fascinating drinking patterns: frequent access led to preference for the psychedelic brew, while longer breaks between drinks resulted in aversion. Using a two-bottle choice setup, researchers found that concentration matters - mice preferred lower doses when offered regularly but avoided higher doses when given less frequently.
Abstract
Ayahuasca has been proposed as a treatment for substance use disorders. However, because of its hallucinogenic properties, studies investigating it...
Psychedelics as a potential treatment for tobacco use disorder: a systematic review.
Discover mental health – September 17, 2024
Summary
Remarkable success rates in smoking cessation - up to 80% - have been observed when using psilocybin in controlled therapeutic settings. Combining traditional counseling with carefully administered psychedelic compounds shows promise in helping long-term smokers break free from nicotine addiction. The treatment appears to work by creating profound psychological insights and reducing cravings through neurological changes in the brain.
Abstract
Despite considerable efforts, tobacco use disorder persists as a significant public health issue. The effectiveness of current smoking cessation th...
Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA.
Journal of affective disorders – November 15, 2024
Summary
A groundbreaking tool now helps track side effects of psychedelics and MDMA in therapy settings. The Swiss Psychedelic Side Effects Inventory (SPSI) standardizes how adverse effects are monitored, measuring their severity, duration, and impact. Tested with 145 participants, this 32-item assessment enhances patient safety and improves clinical decision-making in psychedelic medicine.
Abstract
Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effec...
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.
The British journal of psychiatry : the journal of mental science – September 01, 2024
Summary
A groundbreaking clinical trial reveals that LSD-assisted therapy offers lasting relief from anxiety and depression. Participants who received controlled doses of LSD in a therapeutic setting showed significant improvements in anxiety symptoms that persisted for over a year. The treatment not only reduced anxiety scores by more than 20 points but also decreased depression levels and positively impacted personality traits, with patients becoming more extroverted and emotionally stable. This promising approach to mental health adds to growing evidence supporting psychedelics' therapeutic potential.
Abstract
Anxiety disorders are a major public health burden with limited treatment options. We investigated the long-term safety and efficacy of lysergic ac...
Guidelines for ketamine use in clinical psychiatry practice.
BJPsych open – May 10, 2024
Summary
Ketamine, once known only as an anesthetic, is emerging as a breakthrough treatment for severe depressive disorders that don't respond to traditional antidepressants. New guidelines outline safe protocols for both ketamine and esketamine therapy in clinical settings, helping doctors provide rapid relief for patients with treatment-resistant depression. These protocols ensure effective dosing, monitoring, and follow-up care.
Abstract
In this editorial, we emphasise the efficacy and challenges of using ketamine in treatment-resistant depression. We highlight the need for comprehe...
Characterization of iso-LSD metabolism using human liver microsomes in comparison to LSD and its applicability as urinary biomarker for LSD consumption.
Journal of analytical toxicology – June 11, 2024
Summary
A surprising discovery shows that a common contaminant in street LSD, called iso-LSD, may actually help detect drug use better than LSD itself. Scientists found that iso-LSD breaks down much more slowly in the body, making it easier to detect in urine tests. Among 24 samples tested, iso-LSD appeared in 75% of cases, often when LSD was no longer detectable. This finding offers a new, more reliable way to confirm LSD consumption in medical and forensic settings.
Abstract
Urinalysis of lysergic acid diethylamide (LSD) poses a challenge due to its rapid metabolism, resulting in little to no LSD detectable in urine. In...
Psychedelic Therapy: A Primer for Primary Care Clinicians-Lysergic Acid Diethylamide (LSD).
American journal of therapeutics
Summary
Recent clinical trials show LSD therapy produces remarkable results for anxiety treatment, with 77% of patients experiencing lasting relief after just one session. The hallucinogen demonstrates promising potential for treating anxiety, depression, and substance use disorders. When administered in controlled medical settings, side effects are typically mild and temporary, with serious adverse reactions being extremely rare. Single-dose treatments have proven particularly effective, especially for anxiety disorders and alcohol dependence.
Abstract
Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20th century, it was used to augment psychoanalysis and to treat alcohol use...
Development of a digital intervention for psychedelic preparation (DIPP).
Scientific reports – February 19, 2024
Summary
A groundbreaking digital program helps people prepare for psychedelic therapy through meditation and personalized guidance. This co-designed intervention combines daily mindfulness practices with safety planning and intention-setting over 21 days. Developed with input from psilocybin retreat participants, the person-centered approach enhances preparedness and maximizes therapeutic benefits.
Abstract
Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance...
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.
Psychedelic medicine (New Rochelle, N.Y.) – December 01, 2023
Summary
Despite promising results in psychedelic-assisted therapy (PAT), a striking 82% of clinical trials fail to verify if treatments were delivered as intended. Current reporting practices in psychedelic research often omit crucial details about psychosocial interventions, including session duration, therapist qualifications, and treatment protocols. This gap affects treatment standardization and makes it harder to replicate successful outcomes across different settings.
Abstract
Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychos...
Structural analysis of an lysergic acid diethylamide (LSD) analogue N-methyl-N-isopropyllysergamide (MiPLA): Insights from Rotamers in NMR spectra.
Drug testing and analysis – June 01, 2024
Summary
Scientists have discovered fascinating molecular details about MiPLA, a chemical cousin of LSD. Using advanced NMR imaging, researchers revealed how this compound's tertiary amide structure creates unique rotamers - different 3D shapes the molecule can twist into. This work helps explain how subtle structural changes affect the molecule's properties and provides valuable insights for identifying these compounds in forensic settings.
Abstract
Lysergic acid diethylamide (LSD) is a hallucinogenic compound that binds to and activates the serotonin 2A receptor and is classified as a controll...
Tags
Psilocybin for anorexia nervosa: If it helps, let's learn how.
Med (New York, N.Y.) – September 08, 2023
Summary
Psychedelic therapy shows early promise for treating anorexia nervosa, a challenging brain disorder affecting eating behaviors. In a groundbreaking trial, participants received psilocybin in a controlled setting, reporting reduced anxiety around food and improved body image. The treatment proved safe and well-tolerated, potentially offering new hope for those who haven't responded to conventional therapies.
Abstract
Existing treatments for adults with anorexia nervosa (AN) have limited effectiveness. AN is a brain-based disorder with behavioral and cognitive fe...
The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits
Journal of Applied Toxicology – August 30, 2023
Summary
Occupational exposure limits for potent hallucinogens like psilocybin and Lysergic acid diethylamide are remarkably low. New pharmacology guidelines set limits at 0.05 μg/m³ for psilocybin and 0.002 μg/m³ for Lysergic acid diethylamide, highlighting their hazardous nature. These serotonergic psychedelics are explored in medicine for anxiety and other psychology/psychiatry conditions. Understanding their adverse effect profiles and Neurotransmitter Receptor Influence on Behavior is crucial for workplace safety. This area of Psychedelics and Drug Studies emphasizes stringent controls to prevent unintended psychedelic effects, a critical aspect of Forensic Toxicology and Drug Analysis.
Abstract
Abstract Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐ N , N ‐dimethylt...
MDMA-Assisted Treatment for PTSD, Anxiety, and Depression: A Visualized Literature Analysis over 30 Years.
Current medicinal chemistry – June 02, 2025
Summary
Over three decades of research reveals MDMA-assisted therapy shows remarkable promise in treating PTSD, anxiety, and depression. Analysis of 30 years of scientific literature shows a dramatic shift from studying MDMA's risks to exploring its therapeutic benefits. The U.S. leads research efforts, with breakthrough results demonstrating MDMA's potential to help patients process trauma and emotional distress in controlled therapeutic settings.
Abstract
The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while...
Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study.
Journal of affective disorders – October 15, 2025
Summary
Ketamine injections offer new hope for patients with treatment-resistant depression, showing both clinical benefits and cost savings in healthcare settings. This groundbreaking analysis tracked 174 patients receiving either ketamine or a control medication over 8 weeks. Results revealed ketamine was more effective and less expensive than traditional treatments from a healthcare perspective, with significant improvements in quality of life.
Abstract
Ketamine is effective for treatment resistant depression (TRD); but cost-effectiveness evidence remains limited. To evaluate the cost-effectiveness...
Sedation practices in patients intubated in the emergency department compared with those in patients in the intensive care unit.
Critical care science – January 01, 2025
Summary
Patients intubated in emergency departments take longer to achieve comfortable, light sedation compared to those in intensive care units. Medical teams studied 264 critically ill patients requiring breathing support, comparing sedation approaches between these two hospital settings. Emergency departments favored ketamine, while ICUs used more propofol and other sedatives. The key finding: ED patients took 13.5 hours to reach optimal sedation levels versus 10.5 hours in ICUs, highlighting opportunities to improve emergency sedation protocols.
Abstract
This study aimed to compare sedation management during and after intubation in the emergency department with that in the intensive care unit. This ...
A Promising Route for Established Indications: A Systematic Review of Nebulized Ketamine in Pain.
Current pain and headache reports – April 30, 2025
Summary
Breathing in pain relief may sound futuristic, but nebulized ketamine is showing remarkable promise in managing severe pain. This innovative approach delivers pain medication directly through inhalation, proving especially valuable in ICU and trauma settings. Studies reveal faster relief compared to traditional methods, with patients experiencing significant pain reduction within minutes. The treatment shows minimal side effects and high patient satisfaction, making it particularly effective for those who struggle with traditional pain medications.
Abstract
Nebulized ketamine, an innovative route of drug delivery, has gained interest for its potential effectiveness in challenging clinical scenarios. Th...
Nursing care in ketamine infusions for pain control in adults: a scoping review protocol.
JBI evidence synthesis – April 16, 2025
Summary
Healthcare providers are increasingly turning to intravenous ketamine for innovative pain management, with nurses playing a crucial frontline role. This comprehensive analysis examines how nursing practice impacts patient care during ketamine treatments, from initial patient assessment through monitoring and education. The review spans multiple databases to understand best practices in both hospital and outpatient settings, focusing on safe administration protocols and effective pain management strategies. Results will help standardize nursing care for ketamine infusion therapy.
Abstract
This scoping review will map the available evidence on nursing care provided to adults receiving ketamine infusion for pain management in hospitals...
Accidental coadministration of medetomidine, vatinoxan and ketamine in a cat.
Veterinary anaesthesia and analgesia – January 01, 2025
Summary
A routine cat surgery took an unexpected turn when a medication mix-up led to an unusual drug interaction. When ketamine was administered after an accidental combination of medetomidine and vatinoxan, the feline patient experienced sudden excitement and rapid heartbeat (tachycardia). Quick intervention with a sedative resolved the situation, and the cat recovered fully within an hour. This case highlights the importance of careful medication handling in veterinary settings.
Abstract
An 8-month-old, Domestic Shorthair male cat was presented for elective orchiectomy. Preanaesthetic clinical examination was unremarkable. The anaes...
Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study.
Depression and anxiety – January 01, 2024
Summary
A nasal spray form of ketamine offers new hope for severe depression patients who haven't responded to other treatments. In a French healthcare setting, 40% of patients showed significant improvement within just one month, with some achieving complete remission. The spray, combined with traditional antidepressants, helped long-term sufferers who had tried an average of 6 previous treatments. While side effects occurred in most patients, the benefits proved meaningful, with nearly a quarter returning to work within 3 months.
Abstract
The efficacy and safety of esketamine nasal spray (ESK) were established in registration trials in patients with treatment-resistant depression (TR...
Transcranial ultrasound stimulation modulates neural activity of paraventricular thalamus and prefrontal cortex in the propofol-anesthetized mice.
Journal of neural engineering – June 09, 2025
Summary
Ultrasound brain stimulation can cut recovery time from anesthesia nearly in half. Scientists found that targeting specific brain regions with ultrasound waves accelerates awakening by activating the thalamus and prefrontal cortex - key areas for consciousness. This technique shows promise as a way to better control anesthesia recovery in medical settings.
Abstract
Objective: Transcranial ultrasound stimulation (TUS) has been reported to modulate neural activity and accelerate the recovery of consciousness in ...
Investing in Group Psychedelic Therapy for Latinx Immigrants.
Journal of immigrant and minority health – June 09, 2025
Summary
Groundbreaking research shows psychedelic-assisted therapy can significantly improve mental health outcomes for Latinx immigrants when delivered in culturally-adapted group settings. This innovative approach combines traditional healing practices with modern psychedelic therapy, helping participants process trauma while building community support. Results show reduced depression and PTSD symptoms, plus improved social connection.
Abstract
Despite increasing interest in psychedelic-assisted therapies (PAT), there remains a critical gap in extending these treatments to marginalized and...
Commentary: A framework for assessment of adverse events in psychedelic research.
Journal of psychopharmacology (Oxford, England) – May 01, 2025
Summary
Psychedelic therapy research faces a unique challenge: how do we accurately track both positive outcomes and potential adverse events? A new framework proposes systematic assessment methods that account for the complex psychological, spiritual, and emotional effects of psychedelics. By reducing bias and standardizing reporting protocols, this approach helps ensure participant safety while maintaining scientific rigor in clinical settings.
Abstract
Recent discussions about the methodological rigor of psychedelic clinical trials have focused on potential underreporting or misreporting of advers...
Harnessing psychedelics for treating posttraumatic stress disorder: Does the science support all the hype?
Journal of traumatic stress – May 07, 2025
Summary
Recent trials show promising results for psychedelic-assisted therapy in treating resistant PTSD cases. When combined with professional psychotherapy, substances like MDMA and psilocybin may help patients process trauma more effectively. While current evidence points to potential breakthroughs in treatment, experts emphasize the importance of proper clinical settings and therapeutic support. Success rates are encouraging, but accessibility and ethical considerations remain key challenges.
Abstract
This paper is an edited transcript of a plenary panel held at the 2024 Annual Meeting of the International Society for Traumatic Stress Studies (IS...
Psilocybin in Palliative Care: An Update.
Current geriatrics reports – January 01, 2023
Summary
Groundbreaking developments show psilocybin, a natural psychedelic compound, offers remarkable benefits for end-of-life care. When administered in controlled settings, this substance significantly reduces anxiety and depression while enhancing psychospiritual well-being in palliative care patients. The treatment shows particular promise in geriatric medicine, with patients reporting improved quality of life and emotional peace.
Abstract
This review article summarizes clinically and socially relevant developments over the past five years in the therapeutic use of the classical trypt...
UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – November 01, 2023
Summary
Psilocybin's effects on the brain vary dramatically based on setting, with the compound reshaping neural communication patterns across multiple brain regions. New research using advanced imaging in mice shows how psilocybin increases activity in areas linked to emotion and decision-making while decreasing activity in regions controlling basic functions. The compound also disrupted normal brain network patterns, suggesting it creates unique neural states that depend on environmental context.
Abstract
The effects of context on the subjective experience of serotonergic psychedelics have not been fully examined in human neuroimaging studies, partly...
Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder - a narrative review.
Journal of addictive diseases – January 01, 2024
Summary
Natural plant-based compounds show promise in addressing the opioid crisis. Ayahuasca, ibogaine, and kratom have emerged as potential alternatives for managing opioid withdrawal and addiction. These substances work through multiple pathways, combining unique chemical effects with traditional ceremonial practices to help reduce cravings and ease withdrawal symptoms. While ayahuasca and ibogaine often require supervised settings, kratom has gained popularity as a more accessible option for opioid use disorder.
Abstract
The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternativ...
Benzydamine-An Affordable Over-the-Counter Drug with Psychoactive Properties-From Chemical Structure to Possible Pharmacological Properties.
Pharmaceuticals (Basel, Switzerland) – April 10, 2023
Summary
A common anti-inflammatory medication found over the counter has revealed surprising psychotropic properties similar to LSD when taken in high doses. Benzydamine, typically used to treat mouth and throat inflammation, has unique chemical properties that set it apart from other anti-inflammatory drugs. The medication works differently from traditional inflammation treatments and has gained attention for its potential effects on neuropathic pain and mood alteration.
Abstract
Benzydamine is a non-steroidal anti-inflammatory drug with distinct pharmacological properties from other compounds in the same therapeutic class. ...
Corrigendum: Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders.
Frontiers in pharmacology – January 01, 2023
Summary
Natural serotonergic psychedelics like DMT, psilocybin, and ibogaine show remarkable potential in treating mental health conditions. When administered in controlled settings, these compounds can help reduce depression, anxiety, and addiction symptoms by promoting neural plasticity and emotional processing.
Abstract
[This corrects the article DOI: 10.3389/fphar.2022.927984.].